Quick Answer
Arcus Biosciences, Inc. reported Total Revenue of $247.00 million for fiscal year 2025.
Arcus Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $247.00M -4.3% |
$258.00M +120.5% |
$117.00M +4.5% |
$112.00M -70.8% |
$383.00M +391.0% |
$78.00M +420.0% |
| Revenue (ASC 606) | — | — | $117.00M +4.5% |
$112.00M -70.8% |
$383.00M +391.0% |
$78.00M +420.0% |
| Net Income | -$353.00M -24.7% |
-$283.00M +7.8% |
-$307.00M -15.0% |
-$267.00M -603.8% |
$53.00M +143.1% |
-$123.00M -45.2% |
| Diluted EPS | -$3.29 -4.8% |
-$3.14 +24.3% |
-$4.15 -11.9% |
-$3.71 | — | — |
| Total Assets | $1.14B -1.0% |
$1.15B +5.0% |
$1.09B -18.6% |
$1.34B -15.5% |
$1.59B +106.1% |
$772.29M +280.2% |
| Cash and Equivalents | $222.00M +48.0% |
$150.00M +18.1% |
$127.00M -38.3% |
$206.00M +39.2% |
$148.00M -14.7% |
$173.41M +199.3% |
| Long-Term Debt | $99.00M +106.2% |
$48.00M | $0.00 | — | — | — |
| Stockholders Equity | $631.00M +30.1% |
$485.00M +5.0% |
$462.00M -29.7% |
$657.00M -22.0% |
$842.00M +67.7% |
$502.00M +206.1% |
| R&D Expense | $523.00M +16.7% |
$448.00M +31.8% |
$340.00M +18.1% |
$288.00M +12.1% |
$257.00M +61.6% |
$159.00M +102.6% |
| Operating Income | -$386.00M -17.0% |
-$330.00M +2.9% |
-$340.00M -21.4% |
-$280.00M -618.5% |
$54.00M +143.5% |
-$124.00M -39.8% |
| Shares Outstanding | 125.30M +35.9% |
92.20M +22.1% |
75.50M +3.6% |
72.90M +3.0% |
70.80M +8.7% |
65.11M +41.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $26.00M | -45.8% | -83.8% |
| Revenue (ASC 606) | September 30, 2024 | $48.00M | +50.0% | +23.1% |
| Net Income | September 30, 2025 | -$135.00M | -46.7% | — |
| Diluted EPS | September 30, 2025 | -$1.27 | -27.0% | — |
| Total Assets | September 30, 2025 | $974.00M | -22.2% | -9.4% |
| Cash and Equivalents | September 30, 2025 | $238.00M | +18.4% | -4.0% |
| Long-Term Debt | September 30, 2025 | $98.00M | +108.5% | +1.0% |
| Stockholders Equity | September 30, 2025 | $436.00M | -22.8% | -20.6% |
| R&D Expense | September 30, 2025 | $141.00M | +14.6% | +1.4% |
| Operating Income | September 30, 2025 | -$142.00M | -35.2% | -1675.0% |
| Shares Outstanding | September 30, 2025 | 107.10M | +17.0% | +0.7% |
- Arcus Biosciences, Inc. reported Total Revenue of $247.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed a decrease of -4.3% in Total Revenue compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Revenue (ASC 606) of $117.00 million for fiscal year 2023.
- Arcus Biosciences, Inc. showed an increase of +4.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Net Income of -$353.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed a decrease of -24.7% in Net Income compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Diluted EPS of $3.29 per share (loss) for fiscal year 2025.
- Arcus Biosciences, Inc. showed a decrease of -4.8% in Diluted EPS compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Total Assets of $1.14 billion for fiscal year 2025.
- Arcus Biosciences, Inc. showed a decrease of -1.0% in Total Assets compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Cash and Equivalents of $222.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed an increase of +48.0% in Cash and Equivalents compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Long-Term Debt of $99.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed an increase of +106.2% in Long-Term Debt compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Stockholders Equity of $631.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed an increase of +30.1% in Stockholders Equity compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported R&D Expense of $523.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed an increase of +16.7% in R&D Expense compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Operating Income of -$386.00 million for fiscal year 2025.
- Arcus Biosciences, Inc. showed a decrease of -17.0% in Operating Income compared to the prior fiscal year.
- Arcus Biosciences, Inc. reported Shares Outstanding of 125.30 million shares for fiscal year 2025.
- Arcus Biosciences, Inc. showed an increase of +35.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: